Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake

This study has been completed.
Sponsor:
Collaborator:
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
M. Yannakoulia, Harokopio University
ClinicalTrials.gov Identifier:
NCT01174576
First received: July 26, 2010
Last updated: July 26, 2013
Last verified: July 2013
  Purpose

The purpose of the study is to investigate whether caffeinated and decaffeinated coffee consumption has acute effects on subjective appetite feelings, energy intake and biochemical markers related to appetite, inflammation and glucose metabolism compared to water consumption.


Condition Intervention
Health
Other: caffeinated and decaffeinated coffee

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism

Resource links provided by NLM:


Further study details as provided by Harokopio University:

Primary Outcome Measures:
  • Ghrelin Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Peptide Tyrosine Tyrosine (PYY) Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Glucagon-like Peptide-1 (GLP-1) Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Adiponectin Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 h post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Inteleukin-6 Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Interleukin-18 Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Glucose Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Insulin Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Cortisol Total Area Under the Curve [ Time Frame: 15 min before ingestion to 3 hr post ingestion ] [ Designated as safety issue: No ]
    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150, 180 min postconsumption.

  • Energy ad Libitum Meal [ Time Frame: 3 hr post ingestion ] [ Designated as safety issue: No ]
    The energy of first meal 3 hr after ingestion

  • Total Energy Intake [ Time Frame: 1 d ] [ Designated as safety issue: No ]
    the energy consumed at breakfast, ad libitum meal and rest of the experimental day


Secondary Outcome Measures:
  • Serum Antioxidant Capacity Total Area Under the Curve [ Time Frame: 15 min before ingestion to 21/2 hr post ingestion ] [ Designated as safety issue: No ]

    Serum samples, collected 15 min before ingestion, immediately after ingestion, 15 min, 30 min, 60 min, 90 min, 120 min and 150 min after ingestion were analyzed for the ex vivo serum resistance to oxidative stress, that was induced by copper sulfate (CuSO4). The analysis of all collected samples was performed by the measurement of conjugated diene formation, which was monitored for every sample of all time points every 2 min for a 3.5 h period at 234 nm in a microplate spectrophotometer.

    Total area under the curve was defined as the sum of the areas under and over the baseline using the trapezoidal rule. The time points for the calculations were 15 min before beverage consumption, immediately after beverage consumption, 15, 30, 60, 90, 120, 150 min postconsumption.



Enrollment: 16
Study Start Date: February 2009
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: caffeinated coffee
200 mL caffeinated coffee with 3 mg caffeine per kg body weight
Other: caffeinated and decaffeinated coffee
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
Experimental: decaffeinated coffee
200 mL decaffeinated coffee, same amount as caffeinated coffee
Other: caffeinated and decaffeinated coffee
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
Experimental: Water
200 mL, control intervention
Other: caffeinated and decaffeinated coffee
3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water

Detailed Description:

Coffee is a pharmacologically active, widely consumed beverage. Scientific interest in relation to coffee consumption has been revisited the last decade in the light of new, mainly epidemiological, evidence indicating its potential health benefits. In specific, both cross-sectional and prospective studies indicate that coffee consumption is associated with a lower risk for type 2 diabetes. Furthermore, an inverse association has been found between coffee consumption and markers of inflammation and endothelial dysfunction in healthy and/or diabetic participants, although the opposite effect has also been reported, mainly in relation to inflammation markers. In relation to body weight, epidemiological data suggest that increment in caffeine consumption is associated with lower mean weight gain and energy intake during a 12-y period.

However, information from clinical studies is scarce. Acute caffeine and/or coffee consumption have been associated with impaired glucose metabolism and insulin resistance. In relation to inflammation, animal studies have indicated a beneficial or no effect of coffee consumption, whereas a clinical study in humans found an increase in adiponectin and a decrease in interleukin-18 (IL-18) blood concentrations after a monthly intervention including daily consumption of 8 cups of coffee. As far as energy balance is concerned, there is an early experiment demonstrating that the ingestion of 300 mg of caffeine prior to food intake, compared to the non-caffeine intake, significantly reduced energy intake by 21.7% in men, but not in women. A more recent study has found that the combination of caffeine and red pepper is positively associated with energy expenditure and negatively with energy intake, whereas, it has also been reported a positive association between habitual caffeine intake and body weight loss achieved through a very-low-calorie diet.

Taking into consideration the limited clinical evidence regarding the acute effect of coffee consumption on appetite-related markers, subsequent energy intake and inflammatory markers, we undertook a clinical study of crossover design to investigate the short-term changes on energy intake, subjective appetite ratings, appetite hormones, inflammation markers and glucose metabolism after caffeinated and decaffeinated coffee consumption.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • non-obese

Exclusion Criteria:

  • smokers
  • restrained eaters (as this was evaluated using the Dutch Eating Behaviour Questionnaire and a total score > 2.5)
  • those who reported slimming or any other dietary regime
  • abstainers from caffeine sources
  • athletes during competition period
  • participants with a known diagnosis of either hypertension, diabetes, impaired glucose tolerance or a fasting blood glucose concentration above 125 mg/dl
  • subjects on medication for hypertension or on medication known to alter glucose metabolism
  • subjects who were on medication that may have an impact on appetite and sensory functioning or who reported a metabolic or endocrine disease, gastrointestinal disorders, or a history of medical or surgical events that may have affected the study outcomes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01174576

Locations
Greece
Metabolic Unit of the Department of Nutrition and Dietetics, Harokopio University
Athens, Greece, 17671
Sponsors and Collaborators
Harokopio University
Beth Israel Deaconess Medical Center
Investigators
Study Director: Mary Yannakoulia, PhD Harokopio University
  More Information

No publications provided by Harokopio University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: M. Yannakoulia, PhD, Harokopio University
ClinicalTrials.gov Identifier: NCT01174576     History of Changes
Other Study ID Numbers: CofSt
Study First Received: July 26, 2010
Results First Received: September 4, 2012
Last Updated: July 26, 2013
Health Authority: Greece: Ethics Committee

Keywords provided by Harokopio University:
coffee
appetite
energy intake
inflammation
cortisol
glucose
randomized controlled trial

Additional relevant MeSH terms:
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014